HIV and AIDS Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged over 18 years, both male and female, who are living with HIV-1
- People who have been on a standard three-drug HIV treatment regimen for at least 24 weeks
- People whose doctor has decided, for clinical reasons, that a two-drug simplified treatment (DTG+3TC) may be appropriate — for example, due to difficulty tolerating the standard three-drug treatment, kidney problems, bone density issues, bone marrow problems, or other reasons
- People with a kidney function measurement (creatinine clearance rate) above 50 mL/min (confirm with trial site)
- People who do not have a history of allergy to the study drugs DTG or 3TC
- People who test negative for hepatitis B surface antigen (HBsAg)
- People without chronic liver disease or severe liver damage
- People whose HIV viral load and CD4 cell count at the start of the trial are not restricted to a specific range
- People who are able to attend at least three CD4 monitoring appointments in the first year (at the start, at 24 weeks, and at 48 weeks), and at least every six months after that
- People who have signed the required consent forms for free treatment and for participation in the study
- People who are willing and able to follow the trial requirements consistently
Who may not be able to join:
- People who have taken part in another HIV vaccine or drug clinical trial within the past three months
- People who the research team believes may not be able to complete the scheduled follow-up visits — for example, due to health frailty or difficulty following study requirements
- People who have a known allergy to either of the study drugs, DTG or 3TC
- People who test positive for hepatitis B (HBsAg and/or HBV-DNA)
- People who are pregnant during the study period
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Weiping Cai, Bachelor, Guangzhou 8th People's Hospital
Phone: 020-83710825
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Virus suppression rate; Adverse events
Can't join this trial?
Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.